• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PANOBINOSTAT Drug Record

  • Summary
  • Interactions
  • Claims
  • PANOBINOSTAT chembl:CHEMBL483254 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    PANOBINOSTAT
    FARYDAK
    LBH589
    LBH-589
    LBH 589
    FARYDAK®
    (2E)-N-HYDROXY-3-[4-({[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO}METHYL)PHENYL]ACRYLAMIDE
    pubchem.compound:6918837
    chemidplus:404950-80-7
    chembl:CHEMBL483254
    drugbank:06603
    rxcui:1603350

    Drug Info:

    FDA Approval Multiple myeloma
    Drug Class Small molecule inhibitor
    FDA Approval not approved
    Drug Class small molecule
    Drug Indications antineoplastic agent
    Pharmaceutical Developer Novartis
    Source Reported Drug Name(s) Panobinostat
    Drug Class HDAC Inhibitor
    (5 More Sources)

    Publications:

    Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem
    Beckers et al., 2007, Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group., Int. J. Cancer
    Geng et al., 2006, Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer., Cancer Res.
    Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
    Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
    Scholl et al., 2009, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells., Cell
    Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
    LaBonte et al., 2011, The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models., Cancer Res.
    Landreville et al., 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma., Clin. Cancer Res.
    Muscat et al., 2016, Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors., Clin. Cancer Res.
    Shahbazi J et al., 2016, The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects., Clin Cancer Res
  • PANOBINOSTAT   BAP1

    Interaction Score: 1.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22038994


    Sources:
    CIViC

  • PANOBINOSTAT   SMARCB1

    Interaction Score: 1.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26920892


    Sources:
    CIViC

  • PANOBINOSTAT   MYCN

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26733615


    Sources:
    CIViC

  • PANOBINOSTAT   HDAC1

    Interaction Score: 0.7

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Reported Cancer Type Prostate
    Trial Name Panobinostat

    PMIDs:
    24694055 17455259 17145876


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial CancerCommons TTD

  • PANOBINOSTAT   HDAC3

    Interaction Score: 0.38

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Panobinostat
    Novel drug target Established target
    Notes

    PMIDs:
    24694055


    Sources:
    TALC DTC TdgClinicalTrial

  • PANOBINOSTAT   HDAC6

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name Panobinostat
    Novel drug target Established target

    PMIDs:
    24694055


    Sources:
    TALC DTC TdgClinicalTrial

  • PANOBINOSTAT   HDAC2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Panobinostat
    Notes

    PMIDs:
    24694055


    Sources:
    TALC DTC TdgClinicalTrial

  • PANOBINOSTAT   HDAC9

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Panobinostat
    Novel drug target Established target
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial

  • PANOBINOSTAT   HDAC7

    Interaction Score: 0.31

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Panobinostat
    Novel drug target Established target
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial

  • PANOBINOSTAT   HDAC4

    Interaction Score: 0.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Panobinostat
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome TdgClinicalTrial

  • PANOBINOSTAT   HDAC11

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Panobinostat
    Notes

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial

  • PANOBINOSTAT   HDAC10

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Panobinostat
    Novel drug target Established target
    Notes

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial

  • PANOBINOSTAT   HDAC5

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name Panobinostat
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial

  • PANOBINOSTAT   HDAC8

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name Panobinostat
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TALC TdgClinicalTrial

  • PANOBINOSTAT   KMT2A

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    27443263


    Sources:
    JAX-CKB

  • PANOBINOSTAT   KRAS

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell culture
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    combination therapy Panobinostat + SCH772984

    PMIDs:
    26725216 22693356 19490892


    Sources:
    JAX-CKB

  • PANOBINOSTAT   BRAF

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Lapatinib + Panobinostat
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    21464044


    Sources:
    JAX-CKB

  • MyCancerGenome: PANOBINOSTAT

    • Version: 20-Jun-2017

    Alternate Names:
    FARYDAK Trade Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Multiple myeloma

    Publications:

  • CancerCommons: PANOBINOSTAT

    • Version: 25-July-2013

    Alternate Names:
    Panobinostat PubChem Drug Name
    6918837 PubChem Drug ID
    Panobinostat Drug Trade Name

    Drug Info:
    Drug Class HDAC Inhibitor
    Source Reported Drug Name(s) Panobinostat
    Pharmaceutical Developer Novartis

    Publications:

  • TdgClinicalTrial: PANOBINOSTAT

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class small molecule
    FDA Approval not approved

    Publications:

  • DTC: PANOBINOSTAT

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL483254 ChEMBL Drug ID

    Drug Info:

    Publications:
    Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem

  • JAX-CKB: Panobinostat

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
    Scholl et al., 2009, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells., Cell
    Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell

  • CIViC: PANOBINOSTAT

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Landreville et al., 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma., Clin. Cancer Res.
    Shahbazi J et al., 2016, The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects., Clin Cancer Res
    Muscat et al., 2016, Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors., Clin. Cancer Res.

  • TALC: PANOBINOSTAT

    • Version: 12-May-2016

    Alternate Names:
    PANOBINOSTAT Primary Drug Name
    PANOBINOSTAT Drug Generic Name
    FARIDAK Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Panobinostat

    • Version: 2020.06.01

    Alternate Names:
    D0E3SH TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL483254

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21